356 related articles for article (PubMed ID: 24248375)
1. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
Drake JM; Graham NA; Lee JK; Stoyanova T; Faltermeier CM; Sud S; Titz B; Huang J; Pienta KJ; Graeber TG; Witte ON
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4762-9. PubMed ID: 24248375
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Lee BY; Hochgräfe F; Lin HM; Castillo L; Wu J; Raftery MJ; Martin Shreeve S; Horvath LG; Daly RJ
Mol Cancer Ther; 2014 Jan; 13(1):190-201. PubMed ID: 24194567
[TBL] [Abstract][Full Text] [Related]
3. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Jiang X; Borgesi RA; McKnight NC; Kaur R; Carpenter CL; Balk SP
J Biol Chem; 2007 Nov; 282(45):32689-98. PubMed ID: 17823122
[TBL] [Abstract][Full Text] [Related]
4. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
Huang Y; Kim SO; Jiang J; Frank SJ
J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
[TBL] [Abstract][Full Text] [Related]
5. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.
Drake JM; Graham NA; Stoyanova T; Sedghi A; Goldstein AS; Cai H; Smith DA; Zhang H; Komisopoulou E; Huang J; Graeber TG; Witte ON
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1643-8. PubMed ID: 22307624
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.
Shiota M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Song Y; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Clin Cancer Res; 2014 Feb; 20(4):951-61. PubMed ID: 24352647
[TBL] [Abstract][Full Text] [Related]
7. Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer.
Drake JM; Paull EO; Graham NA; Lee JK; Smith BA; Titz B; Stoyanova T; Faltermeier CM; Uzunangelov V; Carlin DE; Fleming DT; Wong CK; Newton Y; Sudha S; Vashisht AA; Huang J; Wohlschlegel JA; Graeber TG; Witte ON; Stuart JM
Cell; 2016 Aug; 166(4):1041-1054. PubMed ID: 27499020
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.
Yang CC; Fazli L; Loguercio S; Zharkikh I; Aza-Blanc P; Gleave ME; Wolf DA
Oncotarget; 2015 Sep; 6(26):22060-71. PubMed ID: 26091350
[TBL] [Abstract][Full Text] [Related]
9. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of different phospho-tyrosine antibodies for label-free phosphoproteomics.
van der Mijn JC; Labots M; Piersma SR; Pham TV; Knol JC; Broxterman HJ; Verheul HM; Jiménez CR
J Proteomics; 2015 Sep; 127(Pt B):259-63. PubMed ID: 25890253
[TBL] [Abstract][Full Text] [Related]
11. [The modern treatment of metastatic castration-resistant prostate cancer].
Küronya Z; Biró K; Maráz A; Géczi L
Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620
[TBL] [Abstract][Full Text] [Related]
12. Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Babcook MA; Akgul M; Margevicius S; MacLennan GT; Fu P; Abouassaly R; Gupta S
Prostate; 2018 Jul; 78(10):714-723. PubMed ID: 29577356
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
[TBL] [Abstract][Full Text] [Related]
14. Novel Targets and Precision Medicine for Prostate Cancer-Part 2: Tumor Profiling and Personalized Therapy in Patients With Castration-Resistant Prostate Cancer.
Considine B; Petrylak DP
Oncology (Williston Park); 2019 Apr; 33(4):128-31. PubMed ID: 30990564
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
16. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical screening for oncogenic tyrosine kinase activation.
Pulford K; Delsol G; Roncador G; Biddolph S; Jones M; Mason DY
J Pathol; 1999 Apr; 187(5):588-93. PubMed ID: 10398126
[TBL] [Abstract][Full Text] [Related]
18. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.
Morin F; Beauregard JM; Bergeron M; Nguile Makao M; Lacombe L; Fradet V; Fradet Y; Pouliot F
Eur Urol Focus; 2017 Dec; 3(6):639-642. PubMed ID: 28753860
[TBL] [Abstract][Full Text] [Related]
20. Deep Phospho- and Phosphotyrosine Proteomics Identified Active Kinases and Phosphorylation Networks in Colorectal Cancer Cell Lines Resistant to Cetuximab.
Abe Y; Nagano M; Kuga T; Tada A; Isoyama J; Adachi J; Tomonaga T
Sci Rep; 2017 Sep; 7(1):10463. PubMed ID: 28874695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
